This Article Full Text Full Text (PDF) All Versions of this Article: 40/3_suppl_1/S90    most recent STROKEAHA.108.533125v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Selim, M. Search for Related Content PubMed PubMed Citation Articles by Selim, M. Related Collections Acute Cerebral Hemorrhage Other Stroke Treatment - Medical

(Stroke. 2009;40:S90.)
© 2009 American Heart Association, Inc.

Brain Hemorrhage

Deferoxamine Mesylate

A New Hope for Intracerebral Hemorrhage: From Bench to Clinical Trials

From Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.

Correspondence to Magdy Selim, MD, PhD, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. E-mail mselim{at}bidmc.harvard.edu

Iron resulting from hemoglobin degradation is linked to delayed neuronal injury after intracerebral hemorrhage. Extensive preclinical investigations indicate that the iron chelator, deferoxamine mesylate, is effective in limiting hemoglobin- and iron-mediated neurotoxicity. However, clinical studies evaluating the use of deferoxamine in intracerebral hemorrhage are shortcoming. This article reviews the potential role of deferoxamine as a promising neuroprotective agent to target the secondary effects of intracerebral hemorrhage to limit brain injury and improve outcome, and ongoing efforts to translate the preclinical findings into clinical investigations.

Key Words: deferoxamine • ICH • edema • neuroprotection